Cellanyx is augmenting standard pathology with a novel Laboratory Developed Test based on live single tumor cell phenotypic analysis to improve risk stratification of tumor aggressiveness. This first-in-class live tumor cell phenotypic test is designed to provide actionable information on cancer cell aggressiveness to support shared clinical decision-making.
This novel live-cell phenotypic test platform provides unique, and previously inaccessible, cellular and molecular biomarker information to assess temporal and spatial cellular and subcellular features that predict pathobiological behavior and adverse pathology. The phenotypic biomarkers measured using the LPCP (Popup: Live primary cell phenotypic) test resulted in statistically significant predictions of P-SAP (Post-Surgical Adverse Pathology) features in RP (Radical Prostatectomy) specimens. The LPCP test, as a member of a new class of diagnostic/prognostic tests, generated clinically predictive scores:
LAPP (Local Adverse Pathology Potential), and MAPP (Metastatic Adverse Pathology Potential), for the RS (Risk Stratification) of PCa (Prostate Cancer), and has the potential to improve personalized prognosis and treatment guidance in men with newly diagnosed prostate cancer.